Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Cocaine Use Disorder Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering.
The Cocaine Use Disorder Market has experienced substantial growth, evolving from USD 1.29 billion in 2024 to USD 1.36 billion in 2025, with projections indicating further expansion to USD 2.03 billion by 2032 at a CAGR of 5.82%. The dynamic nature of this market necessitates strategic insights, given the multifaceted challenges faced by clinicians, policymakers, and public health officials worldwide.
Recent shifts in regulatory scrutiny and societal attitudes have intensified the need for rapid adaptation to emerging evidence and innovative treatment models. This report serves as a crucial tool for decision-makers, providing comprehensive analysis and strategic context to identify high-impact opportunities and potential risks.
Key Takeaways from This Report
- Advancements in treatment innovations, supported by strategic regulatory changes, are shaping the future of cocaine use disorder management.
- The impact of U.S. tariffs highlights the necessity for resilient supply chains and strategic sourcing decisions.
- Regional analyses reveal diverse market drivers and patient access patterns, emphasizing the need for tailored strategies.
- Industry leaders are investing in integrated care models, blending pharmacological and behavioral interventions for improved patient outcomes.
Market Segmentation & Coverage
This market report explores revenue forecasts and trend analysis in various segments, including:
- Treatment Modality: Behavioral Therapy (Cognitive Behavioral Therapy, Contingency Management, Motivational Interviewing) and Pharmacotherapy (Antidepressants like SSRIs and SNRIs, Psychostimulants).
- Treatment Setting: Inpatient (Detoxification, Residential Rehabilitation) and Outpatient care.
- Indication: Acute and Chronic interventions.
- Diagnostic Tests: Cardiovascular and Neurologic Examinations, Urine Toxicology.
- Payer Type: Out-of-Pocket, Private Insurance, and Public Funding.
- Provider Type: Clinics, Hospitals, and Rehabilitation Centers.
Regional Analysis
This report also dissects trends across key regions:
- Americas: Including North America (United States, Canada) and Latin America (Brazil, Argentina).
- EMEA: Covering Europe, the Middle East, and Africa regions.
- Asia-Pacific: Focusing on growth markets like China, India, and Japan.
Industry Insights & Competitive Strategies
Highlighting competitive strategies, partnerships, and innovations from leading players like Alkermes PLC, Pfizer Inc., and Johnson & Johnson Services, Inc., this report showcases how these organizations are positioning themselves within the market. Strategic alliances, mergers, and acquisitions are vital in consolidating assets and enhancing market positioning, contributing to a more patient-centered care ecosystem.
The report concludes with actionable recommendations for optimizing innovation investments and forging strategic partnerships, thereby guiding stakeholders through the geopolitical challenges in cocaine use disorder management.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 194 |
| Forecast Period | 2025-2032 |
| Estimated Market Value (USD) in 2025 | $1.36 Billion |
| Forecasted Market Value (USD) by 2032 | $2.03 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
Market Insights
- Rapid growth of telepsychiatry platforms delivering remote treatment for cocaine use disorder
- Emergence of long-acting injectable pharmacotherapies targeting cocaine craving and relapse prevention
- Integration of digital phenotyping and machine learning for personalized risk prediction in cocaine use disorder
- Increased investment in anti-cocaine vaccines and monoclonal antibodies to reduce relapse rates
- Expansion of harm reduction initiatives combining drug-checking services with addiction counseling for cocaine users
- Regulatory shifts facilitating fast-track approval pathways for novel anti-addiction compounds targeting cocaine dependence
- Rising utilization of mobile apps and wearable sensors to monitor cocaine use patterns and encourage self-management
- Growth of public-private partnerships funding real-world evidence studies for new cocaine use disorder therapies
- Surge in multidisciplinary telecare models integrating psychiatry, nutrition, and peer support for cocaine addiction
- Development of microdosing protocols for ibogaine analogues as emerging treatment for refractory cocaine use disorder
The companies profiled in this Cocaine Use Disorder market report include:
- Alkermes PLC
- Alnylam Pharmaceuticals, Inc.
- Camurus AB
- Embera NeuroTherapeutics, Inc.
- Indivior PLC
- Johnson & Johnson Services, Inc.
- KemPharm, Inc.
- Kinoxis Therapeutics
- Novartis International AG
- Orexo AB
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Polpharma SA
- Revive Therapeutics Ltd.
- Sage Therapeutics, Inc.
- Saniona AB
- Shionogi & Co., Ltd.
- Sigmapharm Laboratories, LLC
- STALICLA SA
- Teva Pharmaceuticals USA, Inc.
- Viatris Inc.
- Mylan Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/5hjnnc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
